Gelonghui, May 15 | Jinkai Shengke (301509.SZ) said on the investor interactive platform that the company has the technical capability of chiral synthesis. Through chiral synthesis technology, it can control the selectivity of stereosomers during the reaction process, thereby generating new products with specific three-dimensional configurations. The company's expertise in chiral synthesis can provide customized R&D and production services for original pharmaceutical companies around the world to help customers solve the challenges of chiral synthesis in the new drug development process, thereby speeding up the marketing process of new drugs.
金凯生科(301509.SZ)：具备手性合成的技术能力
Jinkai Shengke (301509.SZ): Has the technical ability of chiral synthesis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.